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ABSTRACT:
Somatic defects at five loci, WT1, CTNNB1, WTX, TP53 and the imprinted 11p15 region, are 
implicated in Wilms tumor, the commonest childhood kidney cancer. In this study we analysed 
all five loci in 120 Wilms tumors. We identified epigenetic 11p15 abnormalities in 69% of 
tumors, 37% were H19 epimutations and 32% were paternal uniparental disomy (pUPD). 
We identified mutations of WTX in 32%, CTNNB1 in 15%, WT1 in 12% and TP53 in 5% of 
tumors. We identified several significant associations: between 11p15 and WTX (P=0.007), 
between WT1 and CTNNB1 (P<0.001), between WT1 and pUPD 11p15 (P=0.01), and a strong 
negative association between WT1 and H19 epimutation (P<0.001). We next used these 
data to stratify Wilms tumor into three molecular Groups, based on the status at 11p15 and 
WT1. Group 1 tumors (63%) were defined as 11p15-mutant and WT1-normal; a third also 
had WTX mutations. Group 2 tumors (13%) were WT1-mutant. They either had 11p15 pUPD 
or were 11p15-normal. Almost all had CTNNB1 mutations but none had H19 epimutation. 
Group 3 tumors (25%) were defined as 11p15-normal and WT1-normal and were typically 
normal at all five loci (P<0.001). We also identified a novel clinical association between 
H19 epimutation and bilateral disease (P<0.001). These data provide new insights into the 
pattern, order, interactions and clinical associations of molecular events in Wilms tumor.
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INTRODUCTION
Wilms tumor is the commonest childhood kidney 
cancer and affects 1 in 10,000 children [1]. 5% of 
individuals have bilateral tumors affecting both kidneys 
[2]. Most Wilms tumors occur in otherwise well children. 
Approximately 5% of such children have underlying 
constitutional mutations at WT1 or epigenetic defects at 
chromosome 11p15 that predispose to Wilms tumor [3]. 
Over the past 25 years extensive research has implicated 
somatic abnormalities at five loci in Wilms tumorigenesis. 
These are mutations in WT1, CTNNB1, WTX, TP53 and 
epigenetic 11p15 abnormalities at the imprinted H19/IGF2 
locus [4-11]. 
Despite the considerable number of Wilms tumors 
that have been collected through international trials [12-
15], limited systematic molecular profiling of these loci 
has been performed. A major constraint has been the 
difficulty in undertaking epigenetic analyses at 11p15. 
Two principal somatic abnormalities occur at 11p15: 
paternal uniparental disomy (pUPD 11p15) and H19 
epimutation, also known as IGF2 loss of imprinting [9, 
10, 16-19]. These defects result in H19 hypermethylation 
and biallelic IGF2 expression. In addition, somatic copy 
number defects at 11p15 such as maternal deletions and 
paternal duplications are reported in a small number of 
tumors. Comprehensive 11p15 analysis to detect these 
abnormalities has historically required large amounts of 
tumor sample and multiple, technically demanding assays. 
Thus, although 11p15 defects are by far the commonest 
abnormality in Wilms tumor, disrupted in 50-75% of 
tumors, 11p15 has often not been analysed to completion 
[9, 10, 16-19]. 
To overcome the difficulties of 11p15 profiling, we 
previously optimised a MS-MLPA (methylation-specific 
multiplex ligation-dependent probe amplification) assay 
of 11p15 which allows reliable and comprehensive 
analysis of both epigenetic and copy number defects in a 
single analysis that is cost and time-efficient and requires 
only a small amount of DNA [20, 21]. In this study we 
performed 11p15 MS-MLPA together with mutation 
analyses at WT1, CTNNB1, WTX and TP53 in a series of 
120 Wilms tumors to yield new insights into the patterns 
and interactions of molecular events at the five loci in 
Wilms tumorigenesis. Our series included 100 ‘sporadic’ 
tumors in which constitutional defects at WT1 and 11p15 
had been excluded and 20 cases with constitutional WT1 
or 11p15 defects. The latter were included to facilitate 
investigation into the order of somatic events in tumors 
as, by definition, the constitutional abnormality is the first 
event in such tumors.  
RESULTS
Frequency of somatic mutations in sporadic 
tumors
In the sporadic tumors, the most common somatic 
abnormality was at 11p15, which was abnormal in 69% 
and was due to H19 epimutation in 37% and pUPD 11p15 
in 32%. Monoallelic WTX mutations were present in 32% 
of sporadic tumors. Twenty-one were whole gene deletions 
and three were truncating point mutations. As expected, 
the mutations were hemizygous in males and heterozygous 
in females. Biallelic WT1 abnormalities were detected in 
12% of sporadic tumors and resulted from either a single 
WT1 mutation accompanied by UPD for the mutated 
allele, or two different somatic WT1 mutations. CTNNB1 
mutations were present in 15% and TP53 mutations in 5% 
of sporadic tumors. The frequencies of individual somatic 
abnormalities are similar to those reported in previous 
studies [4, 7-11, 16, 17, 19, 22-29]. The full results are 
given in Supplementary Table 1 and a summary of the 
results in Table 1. 
Frequency of mutations in tumors from 
individuals with constitutional defects
In tumors from individuals with constitutional 
WT1 mutation, the wild-type WT1 allele was somatically 
inactivated in the tumor, either by UPD or by a somatic 
mutation. Seven of the nine tumors had CTNNB1 
 
H19 epimutation (37%)
WTX (32%)
WT1 (12%)
pUPD 11p15 (32%)
CTNNB1 (15%)
11p15 (69%)
Figure 1: Schematic diagram of the overlapping 
distributions of molecular abnormalities at 11p15, 
WTX, WT1 and CTNNB1 in Wilms tumor. The percentage 
of sporadic tumors with each abnormality in our series is indicated 
in brackets. CTNNB1 mutations occur predominantly in tumors 
with WT1 mutations. WTX mutations occur predominantly 
in tumors with 11p15 defects. WT1-mutant tumors often have 
pUPD 11p15 while H19 epimutation, the other class of 11p15 
defect, is not seen in this context. WTX mutations are infrequent 
in tumors with WT1 or CTNNB1 mutations. (pUPD: paternal 
uniparental disomy)
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mutations and the remaining two tumors had WTX 
deletions. In tumors from individuals with constitutional 
11p15 defects there was no additional somatic 11p15 
defect, as expected. Furthermore, no WT1 or CTNNB1 
mutations were detected. Three tumors had WTX deletions. 
The full results are given in Supplementary Table 1 and a 
summary of the results in Table 1. 
Associations between loci
We examined the 120 tumors for associations 
between molecular defects and identified four significant 
associations between abnormalities at different loci 
(Figure 1, Supplementary Table 2). Firstly, we identified 
a strong, novel, positive association between 11p15 and 
WTX defects. WTX mutations were significantly more 
frequent in tumors with 11p15 defects than those without 
(25/61 vs 2/22, P=0.007), and only two WTX-mutant 
tumors had normal 11p15 status (Table 1). The two 
subclasses of 11p15 defect, H19 epimutation and pUPD 
11p15, were present in similar proportions of WTX-
mutant tumors (15/25 vs 10/25). We identified significant 
associations between 11p15 and WT1 mutations, but 
in contrast to WTX, the associations differed according 
to the nature of the 11p15 defect. There was a strong 
negative association between WT1 mutation and H19 
epimutation, which was not found in any WT1-mutant 
tumor (0/17 vs 24/61 P<0.001) consistent with previous 
observational data [23]. In contrast there was a positive 
association between WT1 mutation and pUPD 11p15 
which was present in 12/17 WT1-mutant tumors (12/17 vs 
21/61 P=0.01). Finally, consistent with multiple previous 
studies, CTNNB1 mutations were significantly more 
frequent in tumors with WT1 mutations than those without 
(15/17 vs 2/63, P<0.001) [26, 29, 30]. Each of the three 
TP53-mutant tumors also had H19 epimutation, but this 
association did not reach statistical significance. 
Molecular stratification of Wilms tumor into three 
groups
We examined the patterns of abnormalities at the five 
loci. This allowed us to partition tumors into molecular 
groups according to their status at WT1 and 11p15. The 
Groups are equally applicable to tumors from sporadic and 
constitutional cases and both are included in the Group 
descriptions below. However, it is likely that the relative 
contributions of the Groups to the sporadic tumors better 
reflects the pattern in unselected Wilms tumor series 
(Figure 2, Table 2 and Supplementary Table 1).
Table 1: Results at the five loci in the 120 Wilms tumors.
Sporadic tumors All tumors
n* % n %
Any 11p15 abnormality 62/90 69% 81/110 74%
- H19 epimutation 33 37% 37 34%
- pUPD 11p15 29 32% 44 40%
WTX mutation 24/74 32% 29/87 33%
- WTX deletion 21 28% 26 30%
- Point mutation 3 4% 3 3%
WT1 mutation† 8/66 12% 17/80 21%
- Mutation and UPD WT1 5 8% 12 15%
- Two different mutations 3 5% 5 6%
CTNNB1 mutation 12/79 15% 19/96 20%
TP53 mutation 3/65 5% 3/76 4%
*Denominators at each locus are the number of tumors successfully 
analysed at that locus.
†All WT1-mutant tumors had biallelic mutations; this was either one WT1 
mutation followed by UPD or two separate mutations.
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Group 1 –11p15-mutant, WT1-normal tumors
We defined Group 1 tumors as having an 11p15 
defect but no WT1 mutation. They were the most common, 
accounting for 58% of all tumors and 63% of sporadic 
tumors. We divided Group 1 into two subgroups; Group 
1A tumors which have H19 epimutations (31% of tumors); 
and Group 1B, which have pUPD 11p15 (27% of tumors). 
WTX mutations were present in 32% of Group 1 tumors. 
CTNNB1 mutations were rare, with one CTNNB1 mutation 
identified in a Group 1A tumor and one in a Group 1B 
tumor. TP53 mutations were found in three Group 1A 
tumors.
Group 2 – WT1-mutant, 11p15 pUPD or 11p15-normal 
tumors
We defined Group 2 tumors as those with WT1 
mutations. Group 2 accounted for 22% of all tumors and 
13% of sporadic tumors. The tumors either had 11p15 
pUPD (71%) or were 11p15-normal (29%). CTNNB1 
mutation was present in 88%. WTX mutations were seen 
in a smaller proportion (25%). H19 epimutation was not 
found in any Group 2 tumor.
Group 3– 11p15-normal, WT1-normal tumors
We defined Group 3 tumors as having no 
abnormality at WT1 or 11p15. They accounted for 25% 
of sporadic tumors. CTNNB1, WTX and TP53 mutations 
were not detected in any Group 3 tumor and together were 
significantly less frequent than in Groups 1 and 2 (0/16 
vs 37/62, P<0.001). Thus, the Group 3 tumors were poly-
negative for abnormalities at all five loci.
Clinical associations of molecular groups
The clinical associations of constitutional defects are 
well established and we therefore focussed our analyses 
on evaluating the associations in sporadic tumors, in 
which constitutional WT1 and 11p15 defects had been 
excluded. This revealed two interesting, novel, significant 
associations with younger age at diagnosis and with 
bilateral disease (Table 3, Supplementary Table 3). Age 
at diagnosis was significantly lower in sporadic tumors 
with somatic WT1 mutations (Group 2), compared with 
Group 1 and 3 tumors (14 months vs 38 months, P<0.001). 
Bilateral disease was significantly more frequent in 
sporadic tumors with somatic H19 epimutation (Group 
1A tumors), than other groups (7/23 vs 0/41, P<0.001). 
Furthermore, H19 epimutation was present in three of four 
additional bilateral cases which could not be classified to 
a molecular Group because of failed WT1 analysis. Thus, 
10 of 11 cases with bilateral tumors without constitutional 
mutations had somatic H19 epimutation (P<0.001). In 
the two individuals where tumor was available from both 
kidneys the H19 epimutation was present bilaterally. 
DISCUSSION
Our results identify novel molecular associations 
and in particular clarify the interactions and timing of 
11p15 defects in Wilms tumor. We report a novel, strong 
association between defects at 11p15 and WTX mutations; 
93% of WTX mutations occurred in tumors with 11p15 
Table 2: Frequency of abnormalities at the five loci by molecular Group.
Group 1A Group 1B Group 2 Group 3
n* % n % n % n %
Sporadic tumors 23/64 36% 17/64 27% 8/64 13% 16/64 25%
All tumors 24/78 31% 21/78 27% 17/78 22% 16/78 21%
Any 11p15 abnormality 24/24 100% 21/21 100% 12/17 71% 0/16 0%
- H19 epimutation 24/24 100% 0/21 0% 0/17 0% 0/16 0%
- pUPD 11p15 0/24 0% 21/21 100% 12/17 71% 0/16 0%
WTX mutation 10/23 43% 4/21 19% 3/12 25% 0/16 0%
WT1 mutation 0/24 0% 0/21 0% 17/17 100% 0/16 0%
CTNNB1 mutation 1/24 4% 1/21 5% 15/17 88% 0/16 0%
TP53 mutation 3/22 14% 0/21 0% 0/11 0% 0/16 0%
*Denominators in each Group are the number of tumors successfully analysed at both 11p15 and 
WT1, the two loci used to classify tumors into Groups. Denominators at each locus are the number 
of tumors successfully analysed at that locus.
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defects. Most importantly, we demonstrate that epigenetic 
11p15 defects occur in different contexts and in (at least) 
two distinct types of Wilms tumor that we call Group 1 and 
Group 2 tumors. In Group 1 tumors, which are the most 
common molecular subtype, both classes of 11p15 defect 
occur. It is probable that in Group 1 tumors the 11p15 
defect is an initiating / early event that precedes WTX 
mutation. This is suggested by the occurrence of WTX 
mutation in the tumors with constitutional 11p15 defects, 
in which it must be a secondary event, and also by the 
report of individuals with constitutional WTX mutations 
who have a skeletal dysplasia but do not develop Wilms 
tumor [31].
By contrast, in Group 2 tumors 11p15 defects are 
secondary rather than initiating events, and only one class 
of defect, pUPD 11p15, occurs; H19 epimutation occurs 
very rarely, if at all. In Group 2 tumors, WT1 mutation 
appears to be the initiating / early event (Figure 2). 
Following WT1 mutation, a single somatic recombination 
event causing pUPD encompassing both WT1 and 
11p15 then occurs in a substantial proportion. This will 
simultaneously inactivate the second WT1 allele and cause 
H19 hypermethylation and biallelic IGF2 expression. The 
tumor data from individuals with constitutional defects 
strongly supports this sequence as eight of nine tumors 
from individuals with constitutional WT1 mutations had 
somatic pUPD 11p15, whereas none of 11 individuals with 
constitutional 11p15 defects had somatic WT1 mutations.
A notable observation that emerged from these 
analyses is that Group 3 tumors, which are defined as those 
with normal status at both WT1 and 11p15, were typically 
also negative for mutations at WTX, CTNNB1 and TP53 
(P<0.001, Table 2). In our series this poly-negative group 
accounts for ~25% of tumors. The underlying molecular 
abnormalities in these tumors are currently unknown and 
research focussed on Group 3 tumors may be particularly 
fruitful in the discovery of further Wilms tumor genes.
We detected two novel, significant, clinical 
associations, primarily because we exhaustively 
discriminated tumors with constitutional 11p15 and 
WT1 defects from sporadic tumors. This has rarely been 
undertaken systematically in previous molecular analyses 
of Wilms tumors. The first significant association was 
between sporadic bilateral disease and sporadic Group 
1A tumors; 10 of 11 cases with sporadic bilateral tumors 
had somatic H19 epimutation (P<0.001). A possible 
explanation is that the 11p15 defects that drive these 
tumors occur as early post-zygotic events, and can thus 
be present in both kidneys but absent from lymphocytes. 
This may represent a form of tissue-specific cancer 
predisposition that is intermediate between classic 
constitutional cancer predisposition and tumor-restricted, 
Figure 2: Schematic diagram of the molecular events in tumors in Group 1 and Group 2. Group 1 tumors are defined as 
having 11p15 defects in the absence of a WT1 mutation. Group 1 is subdivided into Group 1A, with H19 epimutation, and Group 1B, 
with pUPD 11p15. In Group 1 tumors, an 11p15 defect occurs as the likely first event, occurring either constitutionally or somatically. 
Approximately 30% of Group 1 tumors undergo WTX mutation, while mutations in TP53 and CTNNB1 mutation are infrequent. No 
additional event is currently identifiable in the majority of Group 1 tumors. Group 2 tumors are defined as having WT1 mutations. In Group 
2 tumors, monoallelic WT1 mutation is the likely first event, occurring either constitutionally or somatically. Group 2 tumors in which the 
mutation targets the paternally-derived WT1 allele frequently next undergo somatic recombination resulting in UPD 11p and causing loss 
of the wild-type WT1 allele and pUPD 11p15. The remainder undergo mutation or deletion of the wild-type WT1 allele and retain normal 
11p15 status. The large majority (~90%) of Group 2 tumors undergo CTNNB1 mutation, while WTX mutation is less common. (pUPD: 
paternal uniparental disomy; UPD: uniparental disomy)
.
        Mutation
paternal WT1 allele
         Mutation 
maternal WT1 allele
or
       UPD 11p causing    
(i) loss second WT1 allele
        (ii) pUPD 11p15
       Mutation
second WT1 allele
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Group 2
CTNNB1 mutation
WTX mutation
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somatic events. If so, it may have relevance to other 
bilateral / multifocal cancers. It is noteworthy that the 
association with sporadic bilateral tumors was restricted 
to H19 epimutation and did not extend to pUPD 11p15. 
This may indicate that either the risk of Wilms tumor is 
higher in H19 epimutation than in pUPD 11p15 tumors 
and/or that H19 epimutation is more likely to occur earlier 
in embryogenesis and hence be present in both kidneys.
The second clinical association that emerged from 
our data is between early age of diagnosis and sporadic 
Group 2 tumors, i.e. tumors with somatic but not 
constitutional WT1 mutations. It is well established that 
most constitutional cancer syndrome mutations, including 
WT1, are associated with younger age of onset. However, 
this association is generally believed to be restricted to 
tumors with constitutional mutations, rather than their 
somatically driven counterparts. This may not be the case 
for Wilms tumors with WT1 mutations, as our analyses 
demonstrate that the median age of onset in children 
with somatic WT1 mutations was 14 months. This is 
significantly lower than the other groups, and the median 
age of sporadic Wilms tumor (38 months) and is similar 
to tumors in children with constitutional WT1 mutations 
[3, 32-34]. The biological explanation for this association 
is obscure, but it may indicate that WT1 mutations are 
associated with a more rapid progression to Wilms tumor 
than other molecular abnormalities.
In summary, through analysis of a series of Wilms 
tumors for molecular defects at the five known Wilms 
tumor genetic loci, this study provides new insights into 
the sequence and patterns of events that occur during 
Wilms tumorigenesis. Similar stratification of tumors 
in large, ongoing clinical trials will allow evaluation of 
these associations in larger numbers with richer clinic-
pathological data, and will likely result in further advances 
in our understanding of the molecular processes that result 
in Wilms tumor and their clinical manifestations. 
METHODS 
Samples
We included 120 individuals affected with Wilms 
tumor recruited by the Wilms Tumor Susceptibility 
Collaboration (WTSC) as part of the Factors Associated 
with Childhood Tumors (FACT) study. The collaborators 
in the WTSC are given in the Supplementary Note. The 
series consisted of 100 sporadic tumors from children 
with non-syndromic Wilms tumor from the UK in whom 
constitutional predisposing defects at WT1 and 11p15 
had been excluded, 9 tumors from individuals with 
constitutional WT1 mutations and 11 from individuals 
with constitutional 11p15 defects (Supplementary Table 
1). Patients and/or their families gave consent for the 
research, which has multicenter research ethics approval 
(MREC05/02/17).
From each case, genomic DNA was extracted from 
tumor and peripheral blood lymphocytes using standard 
techniques. Tumor samples were supplied by the recruiting 
centre for DNA extraction either as fresh frozen or paraffin 
Table 3: Frequency of bilateral disease and median age at diagnosis of sporadic tumors in the three molecular Groups.
Total Bilateral
Age at 
diagnosis 
(months)
n n % median
All tumors classified 64 7 11% 38
Group 1 40 7 18% 42*
1A - H19 epimutation 23 7 30%* 42
1B - pUPD 11p15 17 0 0% 43
Group 2 8 0 0% 14*
Group 3 16 0 0% 39
*Statistically significant associations. P values are given in the text. pUPD: 
paternal uniparental disomy.
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embedded tumor. In all cases, a histological section 
corresponding to the extracted specimen was reviewed by 
a single pathologist. Cases were included in the study only 
if this review confirmed the section to be Wilms tumor and 
that >80% examined nuclei were tumor. The large majority 
of individuals in the series, including all of those with 
sporadic, non-syndromic disease were treated according 
to European protocols, in UK Paediatric Oncology 
centres. In these cases, tumor resection therefore followed 
neoadjuvant chemotherapy (Supplementary Table 3). 
Staging and histological group of tumors was classified 
according to the relevant trial protocol [14, 35-37].
Mutation analysis of WT1, TP53, CTNNB1 and 
WTX
We analysed WT1, TP53 and WTX by direct 
sequencing of their full coding sequences and intron-exon 
boundaries in 10, seven and 11 fragments respectively. We 
analysed the mutation hot-spot of CTNNB1 by sequencing 
of exon 3 as a single fragment. PCR amplification 
was performed on native or whole-genome amplified 
DNA using the primers and conditions specified in 
Supplementary Table 4. Amplicons were then sequenced 
using the BigDyeTerminator Cycle Sequencing Kit and 
an ABI 3730 automated sequencer (Applied Biosystems). 
Mutations in whole-genome amplified samples were 
confirmed in native DNA. Sequence traces were analysed 
using Mutation Surveyor software v3.20 (SoftGenetics) 
and by visual inspection. Only samples in which >90% 
of the coding sequence of a gene was successfully 
screened were considered to have passed at that locus. 
We also performed dosage analysis at WT1 and WTX by 
MLPA (multiplex ligation-dependent probe amplification) 
according to the manufacturer’s instructions using a 
customised version of the P118 WT1 kit (MRC Holland) 
and an ABI 3130 automated sequencer. The P118 kit 
contains 11 probes targeting the 10 exons of WT1 and 
13 probes to flanking genes at 11p13. To allow dosage 
analysis at WTX, we customised the kit by adding four 
synthetic probes targeting the WTX coding sequence, 
two probes targeting the X chromosome outside the 
WTX deletion region and one Y chromosome probe 
(Supplementary Table 5). MLPA traces were analysed 
using GeneMarker v1.51 software (SoftGenetics). For 
WT1 and WTX, samples were required to pass MLPA 
analysis to pass analysis overall at the locus. 
Epigenetic analysis of 11p15
We analysed the imprinted 11p15 region for the 
range of reported methylation and copy number defects 
using methylation-specific MLPA (MS-MLPA) as 
previously described using a customised version of the 
ME030 kit (MRC Holland) [20, 21]. The assay determines 
the level of methylation at two differentially methylated 
regions (DMRs) at 11p15, H19 and KvDMR and also 
copy number at 28 loci across the 11p15 region. Samples 
were classified as follows: (1) Normal methylation and 
normal copy number - No 11p15 defect, (2) Abnormal 
methylation and normal copy number - 11p15 epigenetic 
defect, subclassified according to pattern of abnormal 
methylation such that samples with H19 hypermethylation 
and KvDMR normal methylation were classified as H19 
epimutation whilst those with H19 hypermethylation 
and KvDMR hypomethylation were classified as pUPD 
11p15. (3) Abnormal methylation and abnormal copy 
number - 11p15 copy number defect, deletion (decreased 
copy number) or duplication (increased copy number); 
the parent of origin of the abnormal allele is given by the 
pattern of methylation.
Normal ranges for methylation indices in 
constitutional samples are as previously published 
[20, 21]. To account for the clonal nature of tumor 
DNA, we used more stringent cut-offs for abnormal 
methylation, requiring abnormal tumor samples to 
show >70% methylated alleles. In samples with pUPD 
11p15, we confirmed the abnormality by analysis of 
11p15 microsatellites as previously described [20, 21]. 
Lymphocyte DNA from the proband and available parents 
was analysed in parallel with tumor DNA, allowing the 
parental origin of alleles to be assigned. 
Where an abnormality was identified in tumor DNA, 
we analysed lymphocyte DNA for the same abnormality 
to differentiate constitutional from somatic events. For 
abnormalities identified in a tumor from individuals with 
bilateral disease, we analysed DNA from the contralateral 
tumor if material was available. 
Statistical analysis
We performed comparisons of the frequencies of 
abnormalities at different loci and between molecular 
subgroups using a two-sided Fisher’s exact test. We 
compared the frequencies of bilateral disease and 
unfavorable histology using a two-sided Fisher’s exact 
test and compared stage and age at diagnosis using the 
Wilcoxon rank-sum test.
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